

Barcelona, December 2, 2015

As per section 228 of the restated text of the Securities Market Law approved by the Royal Legislative Decree 4/2015, of October 23 (*texto refundido de la Ley del Mercado de Valores aprobado por el Real Decreto Legislativo 4/2015, de 23 de octubre*) and other applicable provisions, and further to the notice of significant event dated November 2, 2015 (with number 230,408 of the official records), we hereby announce the following:

### **SIGNIFICANT EVENT**

Today, the asset sale offer to purchase for cash (the “**Offer**”) for all of its €325,000,000 4.625% Senior Notes due 2021 (the “**Notes**”) made by Almirall, S.A. (the “**Company**”) that were validly tendered and not withdrawn before 4:00 p.m., London time, on December 1, 2015, has expired (the “**Expiration Date**”).

Holders of Notes who tendered their Notes on or prior to the Expiration Date will receive in cash an amount equal to 100% of the principal amount of the Notes validly tendered plus accrued and unpaid interest, if any, up to and including the date of purchase (“**Repurchase Price**”). The Company expects to pay the Repurchase Price on December 4, 2015.

As of the Expiration Date, €1,450,000.00 in aggregate principal amount of Notes were validly tendered pursuant to the Offer, representing approximately 0.45% of the outstanding aggregate principal amount of the Notes as of the date hereof. All Notes validly tendered and not withdrawn with respect to the Offer were accepted for payment. The Repurchase Price will be €1,461,735.94, the sum of €1,450,000.00 in 100% of the principal amount of the Notes validly tendered and €11,735.94 in accrued and unpaid interest up to and including the date of purchase.

The Bank of New York Mellon is acting as tender agent.

Yours sincerely,

Pablo Divasson del Fraile  
Investors Relations Department  
[inversores@almirall.com](mailto:inversores@almirall.com)

### **ABOUT ALMIRALL, S.A.**

The Company, headquartered in Barcelona, Spain, is a leading pharmaceutical company engaged in the research and development, manufacturing and commercialization of pharmaceutical products, primarily for respiratory and dermatological diseases but also for pain relief and gastrointestinal and other diseases.

This announcement does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Notes and the Guarantees mentioned herein have not been, and will not be, registered under the Securities Act. The Notes and the Guarantees may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. There will be no public offer of the Notes or the guarantees in the United States. Copies of this announcement are not being, and should not be, distributed in or sent into the United States.

It may be unlawful to distribute this announcement in certain jurisdictions. This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any state of the United States and the District of Columbia), Canada, Japan or Australia. The information in this announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Canada, Japan or Australia.

In member states of the EEA, this announcement and any offer of securities if made subsequently is directed only at persons who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (“**Qualified Investors**”). Any person in the EEA who acquires securities in any offer of securities (an “investor”) or to whom any offer of securities is made will be deemed to have represented and agreed that it is a Qualified Investor. Any investor will also be deemed to have represented and agreed that any securities acquired by it in the offer have not been acquired on behalf of persons in the EEA other than Qualified Investors or persons in the UK and other Member States (where equivalent legislation exists) for whom the investor has authority to make decisions on a wholly discretionary basis, nor have the securities been acquired with a view to their offer or resale in the EEA to persons where this would result in a requirement for publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive. The Company and others will rely upon the truth and accuracy of the foregoing representations and agreements.

This communication is being distributed only to, and is directed at (i) persons who are outside the United Kingdom or (ii) persons in the UK falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) the high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “**relevant persons**”). The securities to which this announcement relates are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents. This announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons.